ArticlePloS one2025
Ventricular function assessment using an ultrafast spoiled gradient echo sequence with an intravascular blood pool contrast agent in pediatric patients.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBalanced steady-state free processing (bSSFP) MR sequence has long been considered the gold standard method for ventricular function assessment (VFA), and normal values are based on this acquisition. However, bSSFP sequence suffers from susceptibility artifacts due to scenarios such as cardiac implants. The T1-TFE sequence, also known as ultrafast spoiled gradient sequence, is less affected by such susceptibility artifacts. While it is unclear if T1-TFE sequence yields similar VFA results as the bSSFP sequence. PURPOSE: To validate if the T1-TFE sequence, with an intravascular blood pool contrast agent, yields similar results for VFA as the gold-standard non-contrast bSSFP approach, so that the T1-TFE sequence can be used for VFA when bSSFP approach fails.
methodsTwo sets of images from two different sequences were utilized in this study. T1-TFE (with contrast) scans were used as one while bSSFP-derived images were used as the other. 37 pediatric patients were recruited into this study. Semi-automated software (cvi42) was used to segment and derive ventricular volumes. Image quality was objectively assessed by comparing signal-to-noise (SNR) and contrast-to-noise ratio (CNR) scores. Last, two expert readers provided a subjective analysis of image quality. Paired t-tests were used to assess significant differences in volumetric values (end-diastolic and end-systolic) between T1-TFE and bSSFP sequences. A Bland-Altman analysis evaluated potential bias and agreement between these sequences.
resultsVentricular function assessment via volumetric data analysis resulted in no statistically significant differences (P > 0.05), and high R2 values. SNR and CNR scores also presented with no statistically significant differences (P > 0.05), and nearly identical scores (SNR T1-TFE mean: 29.5 ± 3.1, SNR bSSFP mean: 28.8 ± 3.7, CNR T1-TFE mean: 28.8 ± 3.3, CNR bSSFP mean: 28.1 ± 4.0). Image quality assessment via expert subjective image analysis scores is consistent with the data. All Bland-Altman plots show good agreement and reveal no systematic bias or random error.
conclusionT1-TFE sequences in combination with Ferumoxytol allow reliable ventricular function assessment and overcome the limitations of traditional bSSFP MR sequences in this context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.